Status:
WITHDRAWN
Personalizing Immune Checkpoint Inhibitor Therapy
Lead Sponsor:
Holy Cross Hospital, Maryland
Conditions:
Lung Cancer Stage IV
Eligibility:
All Genders
18-70 years
Brief Summary
This prospective, observational study will evaluate whether vitro testing of tumor tissue and white blood cells from patients with lung cancer who are being treated with immune checkpoint inhibitors a...
Detailed Description
Overall Goal: The long-term goal of this study is to predict whether checkpoint inhibitors will be effective in individual patients with solid tumors. Objectives: In this pilot study to be conducted ...
Eligibility Criteria
Inclusion
- Subjects with lung cancer about to undergo diagnostic/excisional biopsy with the intent to receive therapy with immune checkpoint inhibitors
- Availability of fresh tumor tissue removed at excisional biopsy or diagnostic biopsy
- Informed consent
Exclusion
- • Lack of informed consent
Key Trial Info
Start Date :
February 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 22 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03409341
Start Date
February 1 2019
End Date
September 22 2020
Last Update
September 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Holy Cross Hospital
Silver Spring, Maryland, United States, 20910